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OBJECTIVES: To estimate the cost-consequences of treating
women for Stress Urinary Incontinence (SUI) with a pharma-
ceutical intervention—Duloxetine—from the perspective of the
statutory health insurance in Germany. METHODS: A decision-
tree was developed by a panel of clinical experts to model bi-
annual cost-consequences of three treatment strategies: 1) initial
Duloxetine treatment, followed either by continuation of Dulox-
etine, no further treatment or surgical intervention(s); 2) initial
placebo treatment (physician visits), then no further treatment
or surgical intervention(s); and 3) Standard treatment including
surgical intervention(s). Pelvic Floor Exercises were considered
in all arms. Model input for the ﬁrst three months were taken
from one phase 2 and three phase 3 placebo-controlled studies
assessing the efﬁcacy and safety of Duloxetine. 950 patients with
moderate to severe SUI (Incontinence Episodes Frequency, IEF
>= 14/week) were included in the analysis. Success of treatment
was classiﬁed as “full response” (100% reduction in IEF) and
“successful treatment but not dry” (50.0%–99.9% reduction in
IEF). The likelihood of continuation of Duloxetine beyond three
months was based on the patient’s perception of improvement
as assessed by a validated questionnaire. Success rates for the
considered surgical procedures were drawn from the literature
and expert opinion. Diagnosis Related Groups (2004) for
surgery and the Einheitliche Bewertunsmaßstab (EBM) (2003)
for outpatient resource use were taken to derive costs. Placebo
will not present an option in routine practice, but is presented
because of the clinical trial design. RESULTS: Expected bi-
annual costs per women are: Duloxetine treatment 2205€;
placebo treatment 2034€, and 2092€ for standard treatment.
Duloxetine generates a higher probability of avoiding surgery
(36%), compared with placebo (24%) and standard treatment
(20%). CONCLUSIONS: Treating SUI in women with Duloxe-
tine leads to comparable costs to standard treatment. Model lim-
itations include extrapolation of clinical trial data and parameter
input by clinical experts.
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LONG-TERM COST-EFFECTIVENESS MODELLING OF
FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG
TREATMENT IN PATIENTS WITH BENIGN PROSTATIC
HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS
Hjelmgren J1, Malmberg L2, Ragnarson-Tennvall G1
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2Lund University Hospital, Lund, Sweden
OBJECTIVES: The purpose was to develop an economic model
for simulation of the long-term cost-effectiveness of treatment
with ProstaLund Feedback Treatment (PLFT) versus alpha-
blockade in patients with benign prostatic hyperplasia (BPH) 
and lower urinary tract symptoms (LUTS). The model was
applied using information about Swedish treatment practice.
METHODS: Data from published literature, treatment pro-
grams, and ofﬁcial Swedish price lists was used to develop a
disease progression model for patients with BPH and LUTS
according to the International Prostate Symptom Score (IPSS).
Three important time dependent features of disease progression
were regarded in the model: 1) a phase where initial symptoms
are reduced; 2) a stationary post-treatment phase; and 3) a phase
where the probability of a re-intervention will increase. All the
three phases could be adjusted in the model to capture differ-
ences in treatment effects between different treatment options.
Costs and quality adjusted life years (QALY) were calculated for
a period of three years and discounted at 3%. The calculations
were made in Euro (2003 prices). A sensitivity analysis was per-
formed where scenarios regarding baseline disease severity, treat-
ment effects, time horizon, discount rate, age at initiation of
treatment, QALY weights, and assumption about the probabil-
ity of re-treatment were altered. RESULTS: The total three-year
cost of PLFT (including re-treatment) and alfa-blockade was esti-
mated to 2059€ and 1411€, respectively. According to the model
PLFT would result in 0.07–0.10 more QALYs compared to alfa-
blockade resulting in a cost-effectiveness ratio of €6600–9500.
Due to lower future expected costs of PLFT compared to alfa-
blockade the results indicate that PLFT would be cost-saving if
the time perspective is extended to ﬁve years. CONCLUSIONS:
According to the assumptions made in the model, PLFT is cost-
effective compared to alpha-blockade. The main conclusion
remained stable in the sensitivity analysis.
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LOWER MENTAL HEALTH SCORES MEASURED USING THE
SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF
MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT
THERAPY
García-Mendoza M,Valdés C, Rebollo P, Ortega T, Ortega F
Hospital Universitario Central de Asturias Institute, Oviedo, Spain
OBJECTIVES: To prospectively evaluate the survival of patients
<65 years who initiated hemodialysis (HD) in our region and to
investigate factors associated with survival. METHODS: All
patients < 65 years who started HD in our region between
January, 2001 and September, 2002 and who remained in renal
replacement therapy (RRT) at least 3 months were included and
followed-up to March, 2004 (N = 78). Patients with severe cog-
nitive deterioration were excluded (n = 1). The health related
quality of life (HRQoL) was evaluated using the SF-36 Health
Survey (Physical-PCS and Mental-MCS Component Summary
Scores) and the Kidney Disease Questionnaire (Physical
Symptom scale-PSS) at 3 months from start and at 1 and 2 years
later. Sociodemographic and clinical data, the Karnofsky Scale
score and a comorbidity index were also collected. SF-36 scores
were standardized using the Spanish general population norms.
Kaplan-Meier survival curves and Cox Proportional hazard
regression model were used for the survival analysis. In order to
adjust the effect of age on mortality the Relative Risk of Mor-
tality (RRM) was calculated using the population rates.
RESULTS: At the end, the 2-year survival rate was 88.3%, but
the RRM fell progressively from 30 in the younger patients
(34–43 years) to 6.33 in the older ones (55–64 years). Kaplan-
Meier analysis showed that those with MCS lower than 40 at 3
months from start and those who had not received a kidney
transplant at the second year of the follow-up had lower survival
(p = 0.0074 and 0.0008 respectively). Cox Proportional hazard
regression model with both variables showed that patients with
MCS lower than 40 had higher mortality risk: hazard ratio =
6.94 (95%CI = 1.34–35.99) p = 0.021. CONCLUSIONS:
Patients between 34 and 43 years showed higher RRM. The
mental aspects of the HRQoL could have an important role in
the survival of patients on RRT under 65 years.
PUK14
ELDERLY PATIENTS STARTING RENAL REPLACEMENT
THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED
QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING
THE FIRST TWO YEARS
García-Mendoza M,Valdés C, Ortega T, Rebollo P, Ortega F
Hospital Universitario Central de Asturias Institute, Oviedo, Spain
OBJETIVES: There is already some degree of evidence about the
greater capacity of adaptation to RRT of elderly patients vs. the
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younger ones. The objective of the present study was to assess
the differences 65 years) and younger ones on hemodialysis ≥ in
HRQoL between elderly patients (and renal transplantation
during the ﬁrst two years. METHODS: Longitudinal prospective
study of 199 patients starting RRT. HRQoL was assessed using
the SF-36 health survey at three, 12 and 24 months from the
start of RRT. PCS, MCS and standardised scores by age and sex
were obtained using Spanish general population norms. The t-
student test for unpaired samples was used to compare HRQol
of elderly and younger at each moment. RESULTS: Preliminary
data of 144 patients collected at three months, of 118 at 12
months and of 76 at 24 months are presented. Mean age was
63.5(14.31) and 60.5% were elderly patients. At three months,
all patients were on hemodialysis; elderly patients had lower loss
of HRQoL in Physical Functioning (p = 0.039), Role Physical (p
= 0.005), General 0.0001), Role Emotional (p = 0.014), and PCS
(p = 0.048), than younger < Health (p ones. At 12 months,
elderly transplanted patients had lower loss of HRQoL in Phys-
ical Functioning (p = 0.018), General Health(p = 0.021) and
Vitality (p = 0.067),and elderly patients on hemodialysis had less
loss of HRQL in Physical Functioning (p = 0.002), Role physi-
cal (p = 0.044), Bodily Pain (p = 0.015), General Health (p =
0.001), Mental Health (p = 0.034) and PCS (p = 0.007). At 24
months, elderly transplanted patients had less loss of HRQoL in
Physical Functioning (p = 0.017) Bodily Pain (p = 0.025),
General Health (p = 0.027). CONCLUSIONS: It’s the ﬁrst time
that it is demonstrated that, using standardised scores by age and
gender, elderly patients have less loss of HRQoL than the
younger ones during the ﬁrst year on RRT.
PUK15
PATIENTS UNDERGOING PERITONEAL DIÁLISIS HAVE
BETTER PERCEIVED HEALTH IN SEVERAL SPECIFIC
PROBLEMS RELATED WITH RENAL DISEASE THAN PATIENTS
UNDERGOING HEMODIALYSIS
Valdés C1,Alvarez-Ude F2, Rebollo P1, Estebanez C2
1Hospital Universitario Central de Asturias Institute, Oviedo, Spain;
2Hospital General de Segovia Instutute, Segovia, Spain
OBJECTIVES: Analyze differences in Health Related Quality of
Life (HRQoL) between hemodialysis (HD) and peritoneal dialy-
sis (DP). METHODS: This multicentric study is from 14 dialy-
sis units in our country of a randomized sample of 221 patients,
152 in HD and 69 in DP. HRQoL was evaluated using EuroQoL-
5D scale: 5 dimensions (Mobility-M, Self-Care-SC, Usual Activ-
ities-UA, Pain-P, Anxiety/ Depression-AD) and their Tariff (T),
and the Visual Analogue Scale (VAS). Patients also answered the
KDQOL–SF which includes the SF-36 with the physical and the
mental component summary (PCS, MCS) and speciﬁc questions
about kidney disease. Sociodemographic and clinical data, the
Karnofsky Scale and a comorbidity index were also collected.
SF-36 scores were standardized using the Spanish general popu-
lation norms. RESULTS: Patients undergoing DP were more fre-
quently in employment, had a higher level of education, lower
age (54.4 vs.63.2), less time on dialysis (33.6 vs.48.9 months),
were less often diabetic (10.5%vs.23.3%). However, comorbid-
ity (6.5 vs. 5.6), Karnofsky score (82.2 vs. 84.1), Sf-36 scores
(PCS: 40.9 vs. 40.4; MCS: 47.9 vs. 47.3) and Tariff of EuroQoL-
5D (0.74 vs. 0.70) were similar. Statistically signiﬁcant differ-
ences were found in the VAS (64.7 vs. 55.9; p < 0.001) and in
several speciﬁc dimensions of the KDQOL–SF in which patients
in DP scored higher (better HRQoL): symptoms/problems of
kidney disease (79.7 vs. 75.8; p = 0.05), effects of the renal
disease (72.2 vs. 62.6; p = 0.005), social support (84.8 vs. 78.6;
p = 0.013) and support of the dialysis staff (94.4 vs. 85.03; p =
0.001), although these scores are not standardized for age and
sex in the absence of Spanish population norms for patients in
dialysis. CONCLUSIONS: Patients undergoing DP show similar
status of general health as those of HD, but seem to have a better
perceived health in several speciﬁc problems related with renal
disease. Results emphasize the importance of using, in compar-
ative studies, speciﬁc scales for patients on dialysis.
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VALIDATION OF TWO QUESTIONNAIRES ON SYMPTOMS
AND QUALITY OF LIFE IN ITALIAN WOMEN WITH LUTS: THE
FLOW STUDY
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OBJECTIVES: No validated questionnaires are available for
assessing symptoms and quality of life (QoL) in Italian women
with lower urinary tract symptoms (LUTS). In a large multi-
centre observational study of women with LUTS (FLOW-Female
LUTS: Observational Study in Women), we translated into
Italian and validated the long and short forms of female-speciﬁc
questionnaires (ICIQ-LF and ICIQ-SF). METHODS: The vali-
dation process consisted of forward and backward translation,
test of comprehension, discriminant validity, test-retest reliabil-
ity. A ﬁrst set of women was interviewed after they had ﬁlled in
the questionnaires. A comprehension rate was built as the per-
centage of correctly understood questions and pre-coded answers
of all items by all patients. A case-control study was then per-
formed. Cases were women aged >18 year affected by LUTS
from at least 3 months and with negative dipstick. Controls were
deﬁned as healthy women of comparable age. All women were
enrolled consecutively. In order to evaluate reliability, cases were
retested after seven days and a correlation analysis was per-
formed between the ﬁrst and the second measurement (Pearson’s
r). Discriminant validity was assessed by comparing the scores
of cases and controls with ANOVA. RESULTS: The compre-
hension rate was 99.4% for ICIQ-LF and 99.1% for ICIQ-SF.
Four out of 16 patients did not correctly understand 1 item (hes-
itancy) of ICIQ-LF, which was changed. Cases and controls were
respectively 42 and 47 (ICIQ-SF), 80 and 61 (ICIQ-LF). All the
ICIQ-SF patients were valuable for test-retest, while only 25
patients for ICIQ-LF. Pearson coefﬁcient between ratings was
>0.93 for 23 out of 48 items of ICIQ-LF and 0.96 for ICIQ-SF
total score (p < 0.001). Cases and controls were discriminated
at ANOVA (p < 0.001) with both questionnaires. CONCLU-
SIONS: These data show that ICI questionnaires are generally
easy to understand, have a good to excellent reliability and a
high discriminant validity.
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EVALUATION OF TREATMENT OF FEMALE URINARY
INCONTINENCE WITH THE ICIQ-UI SF QUESTIONNAIRE
Espuña-Pons M1, Rebollo P2, Puig M1
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OBJECTIVES: To evaluate the sensitivity to change of the
Spanish version of the ICIQ-UI SF questionnaire, in order to rec-
ommend its use in clinical practice to evaluate treatment
outcome for Urinary Incontinence (UI). METHODS: Prospective
study of 115 women with diagnostic of Stress UI (SUI) who
received treatment for their incontinence: Pelvic ﬂoor training
(PFT) or surgery. All the patients had clinical and urodynamic
